Pancreatic Cancer Research

ResearcherUniversitat de ValènciaActive in the last 2 years

Luis Sabater-Orti

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-7510-8118; OpenAlex author ID A5079342189. Sources: OpenAlex.

Their work

Papers
11 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: none · 2026: 1 paper

Papers 11

  1. Finding More in Less: Precision Medicine for Pancreatic Cancer Using Residual Cytology Samples. Co-author DOI 10.1111/cyt.70055↗
  2. Short- and long-term outcomes after distal pancreatectomy with radiologic infiltration of splenic vessels for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.gassur.2024.01.018↗
  3. ctDNA whole exome sequencing in pancreatic ductal adenocarcinoma unveils organ-dependent metastatic mechanisms and identifies actionable alterations in fast pr… Co-author DOI 10.1016/j.trsl.2024.05.003↗
  4. Clinical decisions in pancreatic cancer surgery: a national survey and case-vignette study. Co-author DOI 10.1007/s13304-022-01415-1↗
  5. Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review. Co-author DOI 10.3390/cancers13050994↗
  6. Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre. Co-author DOI 10.1136/esmoopen-2020-000929↗
  7. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD… Co-author DOI 10.1007/s00280-018-3682-9↗
  8. Borderline resectable pancreatic cancer. Challenges and controversies. Co-author DOI 10.1016/j.ctrv.2018.06.006↗
  9. mRNA expression profiles obtained from microdissected pancreatic cancer cells can predict patient survival. Last author DOI 10.18632/oncotarget.20076↗
  10. [Recommendations for the diagnosis, staging and treatment of pre-malignant lesions and pancreatic adenocarcinoma]. Co-author DOI 10.1016/j.medcli.2016.07.033↗
  11. High microvessel density in pancreatic ductal adenocarcinoma is associated with high grade. Co-author DOI 10.1007/s00428-013-1409-1↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Andrès M.R. Cervantes · 6 shared papers, 2017–2026 · strength 0.74
  2. Marisol Huerta · 5 shared papers, 2018–2026 · strength 0.68
  3. Marina Garcés‐Albir · 5 shared papers, 2018–2024 · strength 0.61
  4. Clara Alfaro‐Cervelló · 4 shared papers, 2020–2026 · strength 0.60
  5. Susana Roselló · 5 shared papers, 2018–2024 · strength 0.50
  6. Noelia Tarazona · 3 shared papers, 2020–2024 · strength 0.37
  7. Mario Serradilla Martin · 2 shared papers, 2023–2024 · strength 0.35
  8. José Manuel Ramia · 2 shared papers, 2023–2024 · strength 0.35
  9. Dimitri Dorcaratto · 3 shared papers, 2018–2024 · strength 0.32
  10. Raquel Antón‐Peñalver · 1 shared paper, 2026 · strength 0.24
  11. Luis Muñoz‐Bellvís · 1 shared paper, 2023 · strength 0.18
  12. Esteban Cugat Andorrà · 1 shared paper, 2023 · strength 0.18
  13. Silvia Carbonell‐Morote · 1 shared paper, 2024 · strength 0.16
  14. Fernando Rotellar Sastre · 1 shared paper, 2024 · strength 0.16
  15. Gerardo Blanco‐Fernández · 1 shared paper, 2024 · strength 0.16
  16. Maider Ibarrola‐Villava · 1 shared paper, 2021 · strength 0.12
  17. Àngels Ginés Gibert · 2 shared papers, 2016–2018 · strength 0.11
  18. Joan Maurel Santasusana · 2 shared papers, 2016–2018 · strength 0.11
  19. Marta Martín-Richard · 2 shared papers, 2016–2018 · strength 0.11
  20. Ana-Bárbara García-García · 1 shared paper, 2017 · strength 0.06
  21. Laureano Fernández‐Cruz · 1 shared paper, 2018 · strength 0.06
  22. Santiago Sánchez-Cabús · 1 shared paper, 2018 · strength 0.06
  23. Berta Laquente · 1 shared paper, 2018 · strength 0.06
  24. Javier Rodríguez Rodríguez · 1 shared paper, 2018 · strength 0.06
  25. Laura Visa · 1 shared paper, 2018 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.